HIV Infection Clinical Trial
Official title:
Peer Leaders as HIV Risk Reduction Change Agents Among Injection Drug Users (IDUs) in Ukraine
Verified date | June 2019 |
Source | University of Colorado, Denver |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Using a randomized clinical trial (RCT), this study is designed to assess the effectiveness
of HIV (human immunodeficiency virus) risk-reduction interventions targeting injection drug
users (IDUs) in three Ukraine oblasts (regions). The investigators propose to compare the
effectiveness of a revised and updated manually-driven HIV testing and counseling
intervention, the Counseling and Education (C & E) model developed by NIDA, with the C & E
plus a manualized network intervention. At each site, Odessa, Donetsk and Nikolayev, 250
"index members" and 500 of their network members will be recruited through street outreach
over a 32-month period and randomly assigned to C & E alone or C & E plus the network
intervention. Participants will be tested for drug metabolites, interviewed using ACASI
(Audio Computer-Assisted Self-Interviewing), and given a rapid test for HIV at baseline, 6
and 12-months. At six-months, network members will be asked to recruit two others they inject
with but who are not in the study. Primary outcomes include knowledge, self-efficacy,
injection and sex-related risk behavior reduction and partner disclosure among indexes and
primary and secondary network members and intervention diffusion to secondary network
members. The investigators hypothesize more positive and significant change, including
injection and sex risk reduction, intervention diffusion, and partner disclosure, among
indexes as well as first and second network members in the network plus C & E arm compared to
C & E alone. Specific aims include:
1. To compare the effectiveness of the C & E alone with the additive effect of a network
intervention plus C & E in increasing knowledge about HIV and increasing self-efficacy
to practice safer injection and sex-related behaviors among indexes, primary and
secondary network members.
2. To assess the effectiveness of the C & E alone with the additive effect of a network
intervention plus C & E in reducing drug and sex risk behaviors among indexes, primary
and secondary network members.
3. To compare the extent of intervention diffusion to second wave network members in the
two arms.
4. To evaluate the extent of disclosure by HIV positive indexes and network members in the
two arms
Status | Completed |
Enrollment | 2304 |
Est. completion date | March 2017 |
Est. primary completion date | November 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 16 Years and older |
Eligibility |
Inclusion Criteria: - active drug injector - 16 years of age or older - not too intoxicated to give informed consent - not planning to leave the area in the next 6 months and no pending court date that might result in incarceration - agree to HIV testing and counseling - not involved in prior project research activities in teh previous 24 months - Indexes: must be able to recruit two eligible network members into the study - Network: agree to participate in five peer educator training sessions Exclusion Criteria: - being too intoxicated at the time of the interview - impaired mentally due to physical or psychological problems to the point that they cannot voluntarily consent to participate in the study and/or respond to the interview - have a known reason why they will not be available for the intervention or the follow-up interview - have been involved in prior project research activities in the previous 24 months |
Country | Name | City | State |
---|---|---|---|
Ukraine | NGO | Donetsk | |
Ukraine | NGO | Nikolayev | |
Ukraine | NGO | Odessa |
Lead Sponsor | Collaborator |
---|---|
University of Colorado, Denver | National Institute on Drug Abuse (NIDA) |
Ukraine,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | HIV Knowledge | Follow-up interviews at 6 and 12 months | ||
Primary | Self-efficacy regarding HIV risk reduction | Follow-up interviews at 6 and 12 months | ||
Primary | Injection risk behavior reduction | Follow-up interviews at 6 and 12 months | ||
Primary | Sex-related risk behavior reduction | Follow-up interviews at 6 and 12 months | ||
Primary | Intervention diffusion to secondary network members | Follow-up interviews at 6 and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
Active, not recruiting |
NCT02663856 -
My Smart Age With HIV: Smartphone Self-assessment of Frailty
|
||
Completed |
NCT02846402 -
Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda
|
N/A | |
Completed |
NCT02659306 -
Metformin Immunotherapy in HIV Infection
|
Phase 1 | |
Completed |
NCT02663869 -
Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
|
||
Completed |
NCT02921516 -
Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings
|
N/A | |
Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
Active, not recruiting |
NCT02302950 -
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
|
N/A | |
Completed |
NCT01830595 -
Lactoferrin Treatment in HIV Patients
|
Phase 2 | |
Completed |
NCT01852942 -
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
|
Phase 2 | |
Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
Completed |
NCT02269605 -
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment
|
Phase 1 | |
Terminated |
NCT01902186 -
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
|
Phase 4 | |
Completed |
NCT02527135 -
Text Messaging to Improve HIV Testing Among Young Women in Kenya
|
N/A | |
Completed |
NCT02525146 -
Birmingham Access to Care Study
|
N/A | |
Completed |
NCT02118168 -
Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002
|
N/A | |
Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
Active, not recruiting |
NCT02602418 -
Neural Correlates of Working Memory Training for HIV Patients
|
N/A | |
Completed |
NCT01680094 -
Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART
|
Phase 1/Phase 2 |